Abiomed Recalls Over 66,000 Impella Heart Pumps Due to Serious Injury Risk, FDA Classifies as Class I Event
Johnson & Johnson (J&J, NYSE: JNJ), already embroiled in lawsuits over alleged cancer risks associated...
Shanghai Junshi Biosciences Reports 3.38% YOY Revenue Growth in 2023 Financials
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Shenzhen Hepalink Reports 2023 Revenue Dip Amid Sector Demand Declines
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China,...
InnoCare Pharma Reports 2023 Revenue Growth and Pipeline Expansion
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has released its financial report...
Bristol Myers Squibb’s Zeposia Fails to Meet Primary Endpoint in Crohn’s Disease Trial
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a Phase III study for its...
Regenxbio Reports Stable Visual Acuity Improvements with AbbVie’s Gene Therapy in Wet AMD Trial
Regenxbio (NASDAQ: RGNX), the development partner for AbbVie’s (NYSE: ABBV) gene therapy ABBV-RGX-314, has announced...
Gilead Strikes Deal with Xilio Therapeutics for Tumor-Activated IL-12 Candidate
Gilead Sciences (NASDAQ: GILD) has announced an in-licensing agreement with fellow US biotechnology company Xilio...
Alphamab Oncology Reports 31.12% Revenue Growth in 2023 with Continued R&D Focus
Alphamab Oncology (HKG: 9966), a Chinese biopharmaceutical company, has released its financial performance and business...
Bio-Thera Solutions Reports 54.86% YOY Revenue Growth in 2023, Led by Biosimilar Sales
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company headquartered in Guangzhou, has announced its financial results...
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with...
Jiangsu Hengrui’s SHR-A1921 Earns FDA Fast-Track Status for Platinum-Resistant Ovarian Cancer Therapies
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a distinguished pharmaceutical entity, has announced that it...
Hengrui Pharmaceuticals Advances Clinical Trial for PD-L1 Inhibitor Combo in CLDN18.2 Positive Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company, has received approval from...
Allergan Aesthetics Launches SKINMEDICA in China, Targeting Booming Skincare Market
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the market launch of its...
InnoCare Pharma Initiates Phase Ib Study Combining ICP-189 with Furmonertinib for NSCLC
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company , has announced that the first...
Novatim Immune Therapeutics’ KQ-2003 Gains Tacit Approval for POEMS Syndrome Clinical Trial in China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd, a China-based specialist in cancer immunotherapy, has received tacit...
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge...
Hepalink’s Enoxaparin Sodium Injection Receives Marketing Approval in New Zealand
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a prominent pharmaceutical company based in China,...
IASO Biotherapeutics Gets NMPA Go-Ahead for BCMA-Targeted CAR-T Therapy Clinical Trial
IASO Biotherapeutics, a China-based biopharmaceutical company, has announced that it has received approval from the...
WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer
WuXi AppTec (SHA: 603259, HKG: 2359), a leading Contract Research, Development, and Manufacturing Organization (CRDMO)...
China’s National Joint Procurement Office Announces Renewal of Insulin Procurement Contracts Valued at $1.59 Billion
The National Joint Procurement Office in China has announced the renewal of drug procurement contracts...